CJC-1295/Ipamorelin
Ships fully reconstituted · no mixing, no powder, no bacteriostatic waterPulsatile Growth Hormone Release
Gold-standard GH combo for synergistic fat loss, muscle gain, and deeper sleep.
Choose your supply
Extra 10% off your first order · use code WELCOME10 at checkout (stacks with the supply discount above).
Frequently paired with
What it supports
- Enhanced fat loss especially visceral fat
- Increased lean muscle mass
- Improved strength and exercise capacity
- Better sleep quality and deeper REM cycles
- Enhanced recovery from training
- Supports metabolic function
- Clean GH release with minimal side effects
The details
- Administration
- Subcutaneous injection, evening
- Format
- 1.2mg/mL, 5mL vial
- Typical dosing
- CJC-1295 1-2mg + Ipamorelin 200-300mcg subcutaneously before bed
- Best for
- Body composition, fat loss, muscle gain, sleep
- Pairs well with
- Sermorelin, MOTS-C
- Mechanism
- CJC-1295 (no-DAC, Modified GRF 1-29) binds GHRH receptors with a short, roughly 30-minute action that primes the pituitary while keeping release pulsatile. Ipamorelin selectively binds ghrelin receptors to trigger a clean GH pulse without affecting cortisol or prolactin. The dual-pathway approach amplifies natural GH output while preserving the body's feedback mechanisms.
How it works
Signal
CJC-1295/Ipamorelin is given as a single subcutaneous injection in the evening, on an empty stomach — the timing stacks the peptide-driven pulse on top of your natural nighttime GH release.
Cellular response
CJC-1295 binds GHRH receptors with an extended half-life for continuous GH stimulation; Ipamorelin selectively binds ghrelin receptors to add clean GH pulses without raising cortisol or prolactin. Together the two pathways amplify natural GH output while preserving the body’s feedback rhythm.
Outcome
Over the following weeks most people notice deeper sleep first (weeks 1–2), then faster recovery and early fat loss (weeks 3–6), then visible body-composition changes (weeks 6–10). Your provider rechecks IGF-1 along the way to keep you in a healthy range.
Sources & references
Sustained GH and IGF-1 elevation in humans (CJC-1295)
Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799–805.
View sourceIpamorelin: the first selective GH secretagogue
Raun K et al. Eur J Endocrinol. 1998;139(5):552–561.
View sourceGH secretagogues and body composition (review)
Sigalos JT & Pastuszak AW. Peptide therapeutics review, 2020.
View sourceCJC-1295 prolonged half-life pharmacology
Journal of Clinical Endocrinology & Metabolism, 2006
View sourceIpamorelin selective GH release
European Journal of Endocrinology, 1998
View sourceEffects on lean body mass and IGF-1
Growth Hormone & IGF Research, 2010
View sourceSafety of GHRH analogs in adult-onset GH deficiency
Endocrine Reviews, 2018
View source
Common questions
Important safety information
CJC-1295/Ipamorelin is available by prescription only and is dispensed after a licensed provider reviews your medical screening and determines it is appropriate for you. Compounded medications are prepared by a licensed U.S. pharmacy and are not FDA-approved products. Tell your provider about your full medical history and any medications you take.
- • May cause temporary water retention
- • Possible injection site reactions
- • Should not be used with active cancer
- • Requires licensed provider supervision